Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry.

Molecular analysis of circulating and disseminated tumor cells (CTCs/DTCs) has great potential as a means for continuous evaluation of prognosis and treatment efficacy in near-real time through minimally invasive liquid biopsies. To realize this potential, however, methods for molecular analysis of these rare cells must be developed and validated. Here, we describe the integration of imaging mass cytometry (IMC) using metal-labeled antibodies as implemented on the Fluidigm Hyperion Imaging System into the workflow of the previously established High Definition Single Cell Analysis (HD-SCA) assay for liquid biopsies, along with methods for image analysis and signal normalization. Using liquid biopsies from a metastatic prostate cancer case, we demonstrate that IMC can extend the reach of CTC characterization to include dozens of protein biomarkers, with the potential to understand a range of biological properties that could affect therapeutic response, metastasis and immune surveillance when coupled with simultaneous phenotyping of thousands of leukocytes.

[1]  Wolfgang Huber,et al.  EBImage—an R package for image processing with applications to cellular phenotypes , 2010, Bioinform..

[2]  J. Buhmann,et al.  Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry , 2014, Nature Methods.

[3]  J. Gratama,et al.  Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1 , 2009, Cytometry. Part B, Clinical cytometry.

[4]  Serge Beucher,et al.  Watershed, Hierarchical Segmentation and Waterfall Algorithm , 1994, ISMM.

[5]  T. Fehm,et al.  Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. , 2013, Anticancer Research.

[6]  E. Hurt,et al.  CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis , 2008, British Journal of Cancer.

[7]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[8]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[9]  J. Hicks,et al.  Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. , 2018, Convergent science physical oncology.

[10]  G. Nolan,et al.  Mass Cytometry: Single Cells, Many Features , 2016, Cell.

[11]  Sean C. Bendall,et al.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.

[12]  C. Wood,et al.  Tumor-suppressive activity of CD66a in prostate cancer , 1999, Cancer Gene Therapy.

[13]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[14]  Polina Golland,et al.  Voronoi-Based Segmentation of Cells on Image Manifolds , 2005, CVBIA.

[15]  M. Gross,et al.  Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line , 2012, Physical biology.

[16]  Emma Lundberg,et al.  A proposal for validation of antibodies , 2016, Nature Methods.

[17]  Daniel Grolimund,et al.  Fast chemical imaging at high spatial resolution by laser ablation inductively coupled plasma mass spectrometry. , 2013, Analytical chemistry.

[18]  Joshua M. Kunken,et al.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers , 2012, Physical biology.

[19]  K. Pantel,et al.  Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape , 2017, Nature Reviews Clinical Oncology.

[20]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[21]  Karel Drbal,et al.  CD molecules 2005: human cell differentiation molecules. , 2005, Blood.

[22]  Sabine Tricot,et al.  Evaluating the efficiency of isotope transmission for improved panel design and a comparison of the detection sensitivities of mass cytometer instruments , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[23]  C. Garbe,et al.  Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients , 2017, The Journal of Immunology.

[24]  Dalin He,et al.  Role of Wnt/β‐catenin signaling pathway in epithelial‐mesenchymal transition of human prostate cancer induced by hypoxia‐inducible factor‐1α , 2007 .

[25]  J. Kendall,et al.  Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells , 2014, PloS one.

[26]  P. Troncoso,et al.  Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters , 2016, Clinical Cancer Research.

[27]  William J. Howat,et al.  Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers , 2014, Methods.

[28]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[29]  G. Nolan,et al.  The road ahead: Implementing mass cytometry in clinical studies, one cell at a time , 2017, Cytometry. Part B, Clinical cytometry.